Amazing observation!
Posts tagged Value Pickr
Investment journey of a late starter (28-06-2024)
Since my last general portfolio update here at the end of 2023, the portfolio is up by about 33% in past 6 months. Since the portfolio has grown at about 60% CAGR. for 2 years. I have taken the decision to became a little defensive and accordingly increased the percentage of low beta investments like large caps ( Larsen & Toubro, Tata Motors, cg power - Asian paints etc.), power grid invit etc.
Portfolio churn has increased of late and only 15 stocks out of 40 has been with me for longer than 6 months . However, those 15 stocks are worth more than 50% of the portfolio .
Because of the volatility of late , I had decided to book when profit was there to be taken and triggers were not in near future.
As a result , at present I don’t have a few stocks that I consider good for long term but I intend to buy those back later .
I have let go of almost all so called long term bets like AEGIS( sad sad mistake), SIRCA, HBL ,Shivalik ,Indigo paints , AngelOne , INTELLECT etc. While Aegis has tripled once I sold it after running in circles for 2 years , the rest have not gone anywhere but backwards mostly.
I have added CMSINFO(avg 400), SHARDA MOTORS(avg 1578),BKT(avg 3015 ), NATCO(avg 1202)BOMBAYDYEING(175) , ANURAS(772) etc. in past 2 months along with riskier and smaller bets like WPIL(3680), EIMCO(1575), PGEL(2520), WALCHANDNAGAR(220), SHILCHAR(4500) and
THOMASSCOTT(260) etc.
Once one has got a 20 bagger like Piccadily , it’s impossible to resist the urge to find another like it . It’s also true that one can’t know beforehand . So pick 5 and hope one makes it worth it .
One thing I am struggling with is allocation larger amount to a single stock in proportion to rising portfolio value . Hope I get better at it soon .
Rishi Laser- A Precision Fabricator (28-06-2024)
Thanks @venkatesan - This was helpful.
Will start tracking the same.
@rk1771 - Have you ever interacted with the management or visited their plant? You seem to be tracking this for 13 years now. Can we get further information from contacting them?
Shilchar Technologies – Power & Distribution Transformers – Sunrise Sector? (28-06-2024)
Recently CareEdge has upgraded Credit Ratings of Shilchar on account of improved performance.
One interesting point I found in the ratings report is hidden guidance of 700 revenue by the management.
To dig deeper if we check these credit reports of last 3 years we can clearly see the number given in those reports is matched or exceeded by the company
In 2021-22 they did 180 crores against guidance of 175 crores in credit report. Similarly, in
2022-23 280 crores against guidance of 250 crores and in
2023-24 397 crores against guidance of 400 crores.
Surprisingly, management is guiding for 700 crores revenue despite delay in capex by four months for phase-1 and one month for phase-2. But again, the company has so far over delivered on every front and have been quite no-nonsense and that gives confidence.
In my opinion if they achieve this 700 crores, in ideal world this could be approximately 100 crores, 150 crores, 200 crores and 250 crores for Q1, Q2, Q3 and Q4 respectively with some hits and misses.
NCC: Extremely undervalued (28-06-2024)
Anyone that has been tracking NCC since a long time, could you explain how post 2019 the cash conversion cycle went from `126 crore to -126 crore, and it has been negative ever since.What explains a change this drastic?
Sanghvi Movers (28-06-2024)
that too by taking revenue and profitability, as is being guided by mgmt. for FY25. Besides, there will be capex of Rs 150-200 crores, for which they will be raising long term debt, @ around similar cost and addl depreciation cost. In all likelihood, the earnings will degrow from FY24…
Sanghvi Movers (28-06-2024)
that too by taking revenue and profitability, as is being guided by mgmt. for FY25. Besides, there will be capex of Rs 150-200 crores, for which they will be raising long term debt, @ around similar cost and addl depreciation cost. In all likelihood, the earnings will degrow from FY24…
Orchid Pharma Ltd (28-06-2024)
Orchid pharma partnered with Cipla to launch Cefepime-Enmetazobactum in India.
This is probably one of the best thing done by Orchid in marketing new drug.
Definitely there will more interest for novel drug + known company(Cipla) than novel drug+ not a known company( Orchid), not purely based on scientific reasons though. Many professional would not have heard orchid pharma name , where as Cipla is established company with good presence, brands and already supplying many antimicrobials like Tazact(pipercillin tazobactum),Merocrit( meropenem) , Vanlid( vancomycin), Tiganex( tigecycline) etc…which are used in hospitals/critical care.
Even though Orchid has mentioned that they will be launching their own hospital division in few quarters that would have delayed the ramp up in sales and reach across the country.
Orchid Pharma Ltd (28-06-2024)
Orchid pharma partnered with Cipla to launch Cefepime-Enmetazobactum in India.
This is probably one of the best thing done by Orchid in marketing new drug.
Definitely there will more interest for novel drug + known company(Cipla) than novel drug+ not a known company( Orchid), not purely based on scientific reasons though. Many professional would not have heard orchid pharma name , where as Cipla is established company with good presence, brands and already supplying many antimicrobials like Tazact(pipercillin tazobactum),Merocrit( meropenem) , Vanlid( vancomycin), Tiganex( tigecycline) etc…which are used in hospitals/critical care.
Even though Orchid has mentioned that they will be launching their own hospital division in few quarters that would have delayed the ramp up in sales and reach across the country.